Ovarian Cancer (Vaccines)

Phase II/III Clinical Trial Requested

Published in Women's Health Weekly, August 19th, 1996

AltaRex Corporation announced it has filed an IND submission with the Health Protection Branch of Canada (HPB) for a Phase II/III clinical trial of its lead product, Ovarex^TM vaccine. The randomized, blinded, placebo-controlled trial will be conducted in numerous major cancer centers across Canada from Vancouver to Halifax.

AltaRex intends to enroll more than 200 patients with advanced ovarian cancer in this study. "We are very pleased to achieve this important milestone, and to be able to bring the benefits of the technology we have tested in Europe for a number of years to North America," said Dr. A. Noujaim, the AltaRex's president and CEO.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (1996-08-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry